HBV-related HCC, clinical issues and therapy

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Every year, more than 600 thousand persons will develop hepatocellular carcinoma (HCC) worldwide. Sixty percent of all HCCs in Asia and Africa are related to chronic infection with the hepatitis B virus (HBV) compared to only 20% of HCC cases in Europe, Japan and USA. Surveillance of chronically infected patients improves treatment of HCC, since it helps detecting tumors amenable to radical therapies. In cirrhotic patients, HCC can be confidently diagnosed by contrast imaging techniques, albeit the accuracy of radiological diagnosis is largely influenced by tumor size. Hepatic resection and liver transplantation are the first therapeutic options for patients within Milan criteria. The long-term outcome of resection, however, is affected by high risk of tumor recurrence, whereas liver transplantation has a negligible risk of both HBV and HCC recurrence-related anticipated mortality. The clinical benefits of loco-regional ablative techniques are evidence based for patients with less than 3 cm tumors only, whereas the standard of care for intermediate tumors, chemoembolization, needs to be validated in view of new technical improvements. Tertiary prevention of HCC in patients with established HBV infection is doubtful, mainly due to methodological weaknesses of studies based on interferon and nucleos(t)ide analogues therapy.

Original languageEnglish
JournalDigestive and Liver Disease
Volume43
Issue numberSUPPL. 1
DOIs
Publication statusPublished - Jan 2011

Fingerprint

Hepatitis B virus
Hepatocellular Carcinoma
Liver Transplantation
Neoplasms
Therapeutics
Tertiary Prevention
Recurrence
Virus Diseases
Standard of Care
Interferons
Japan
Mortality
Infection

Keywords

  • Cirrhosis
  • Hepatitis B virus
  • Hepatocellular carcinoma

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

HBV-related HCC, clinical issues and therapy. / Iavarone, Massimo; Colombo, Massimo.

In: Digestive and Liver Disease, Vol. 43, No. SUPPL. 1, 01.2011.

Research output: Contribution to journalArticle

@article{e728e97a23a0497287d7c236bd672cab,
title = "HBV-related HCC, clinical issues and therapy",
abstract = "Every year, more than 600 thousand persons will develop hepatocellular carcinoma (HCC) worldwide. Sixty percent of all HCCs in Asia and Africa are related to chronic infection with the hepatitis B virus (HBV) compared to only 20{\%} of HCC cases in Europe, Japan and USA. Surveillance of chronically infected patients improves treatment of HCC, since it helps detecting tumors amenable to radical therapies. In cirrhotic patients, HCC can be confidently diagnosed by contrast imaging techniques, albeit the accuracy of radiological diagnosis is largely influenced by tumor size. Hepatic resection and liver transplantation are the first therapeutic options for patients within Milan criteria. The long-term outcome of resection, however, is affected by high risk of tumor recurrence, whereas liver transplantation has a negligible risk of both HBV and HCC recurrence-related anticipated mortality. The clinical benefits of loco-regional ablative techniques are evidence based for patients with less than 3 cm tumors only, whereas the standard of care for intermediate tumors, chemoembolization, needs to be validated in view of new technical improvements. Tertiary prevention of HCC in patients with established HBV infection is doubtful, mainly due to methodological weaknesses of studies based on interferon and nucleos(t)ide analogues therapy.",
keywords = "Cirrhosis, Hepatitis B virus, Hepatocellular carcinoma",
author = "Massimo Iavarone and Massimo Colombo",
year = "2011",
month = "1",
doi = "10.1016/S1590-8658(10)60690-1",
language = "English",
volume = "43",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier B.V.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - HBV-related HCC, clinical issues and therapy

AU - Iavarone, Massimo

AU - Colombo, Massimo

PY - 2011/1

Y1 - 2011/1

N2 - Every year, more than 600 thousand persons will develop hepatocellular carcinoma (HCC) worldwide. Sixty percent of all HCCs in Asia and Africa are related to chronic infection with the hepatitis B virus (HBV) compared to only 20% of HCC cases in Europe, Japan and USA. Surveillance of chronically infected patients improves treatment of HCC, since it helps detecting tumors amenable to radical therapies. In cirrhotic patients, HCC can be confidently diagnosed by contrast imaging techniques, albeit the accuracy of radiological diagnosis is largely influenced by tumor size. Hepatic resection and liver transplantation are the first therapeutic options for patients within Milan criteria. The long-term outcome of resection, however, is affected by high risk of tumor recurrence, whereas liver transplantation has a negligible risk of both HBV and HCC recurrence-related anticipated mortality. The clinical benefits of loco-regional ablative techniques are evidence based for patients with less than 3 cm tumors only, whereas the standard of care for intermediate tumors, chemoembolization, needs to be validated in view of new technical improvements. Tertiary prevention of HCC in patients with established HBV infection is doubtful, mainly due to methodological weaknesses of studies based on interferon and nucleos(t)ide analogues therapy.

AB - Every year, more than 600 thousand persons will develop hepatocellular carcinoma (HCC) worldwide. Sixty percent of all HCCs in Asia and Africa are related to chronic infection with the hepatitis B virus (HBV) compared to only 20% of HCC cases in Europe, Japan and USA. Surveillance of chronically infected patients improves treatment of HCC, since it helps detecting tumors amenable to radical therapies. In cirrhotic patients, HCC can be confidently diagnosed by contrast imaging techniques, albeit the accuracy of radiological diagnosis is largely influenced by tumor size. Hepatic resection and liver transplantation are the first therapeutic options for patients within Milan criteria. The long-term outcome of resection, however, is affected by high risk of tumor recurrence, whereas liver transplantation has a negligible risk of both HBV and HCC recurrence-related anticipated mortality. The clinical benefits of loco-regional ablative techniques are evidence based for patients with less than 3 cm tumors only, whereas the standard of care for intermediate tumors, chemoembolization, needs to be validated in view of new technical improvements. Tertiary prevention of HCC in patients with established HBV infection is doubtful, mainly due to methodological weaknesses of studies based on interferon and nucleos(t)ide analogues therapy.

KW - Cirrhosis

KW - Hepatitis B virus

KW - Hepatocellular carcinoma

UR - http://www.scopus.com/inward/record.url?scp=78650638975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650638975&partnerID=8YFLogxK

U2 - 10.1016/S1590-8658(10)60690-1

DO - 10.1016/S1590-8658(10)60690-1

M3 - Article

VL - 43

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - SUPPL. 1

ER -